256 related articles for article (PubMed ID: 16222152)
1. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
[TBL] [Abstract][Full Text] [Related]
2. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
3. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
5. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Azzariti A; Xu JM; Porcelli L; Paradiso A
Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
[TBL] [Abstract][Full Text] [Related]
6. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
9. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
10. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
[TBL] [Abstract][Full Text] [Related]
11. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Yashiro M; Qiu H; Hasegawa T; Zhang X; Matsuzaki T; Hirakawa K
Br J Cancer; 2011 Nov; 105(10):1522-32. PubMed ID: 21997136
[TBL] [Abstract][Full Text] [Related]
12. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract][Full Text] [Related]
13. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
Yang L; Li J; Ran L; Pan F; Zhao X; Ding Z; Chen Y; Peng Q; Liang H
J Gastrointest Surg; 2011 Jun; 15(6):942-57. PubMed ID: 21479670
[TBL] [Abstract][Full Text] [Related]
15. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
17. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
Asbagh LA; Vazquez I; Vecchione L; Budinska E; De Vriendt V; Baietti MF; Steklov M; Jacobs B; Hoe N; Singh S; Imjeti NS; Zimmermann P; Sablina A; Tejpar S
Oncotarget; 2014 Oct; 5(20):10070-83. PubMed ID: 25301722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
